Citius Pharmaceuticals' (CTXR) unit Citius Oncology (CTOR) said Tuesday it signed a distribution agreement with Cencora to expand a commercial distribution network for Lymphir, a treatment for relapsed or refractory cutaneous T-cell lymphoma.
Under the agreement, Cencora will operate as a wholesale distributor for the treatment, enhancing access and availability of Lymphir across treatment centers in the US, the company said.
Financial terms of the deal were not disclosed.
CTXR and CTOR shares were up 6.6% and 1.5%, respectively, in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.